ENERGIZE THE FIGHT.
BREAKING NEWS: FDA APPROVES TK2D THERAPY
The U.S. Food and Drug Administration (FDA) has approved UCB’s Kygevvi (doxecitine and doxribtimine) to treat the mitochondrial disease TK2d. “It’s hard to put into words what today’s decision means for patients living with TK2d,” said UMDF President and CEO Kristen Clifford. READ MORE >>
UMDF To Host Special Ask the Mito Doc Focused on TK2d Therapy Kygevvi with Dr. Michio Hirano: Join us for a special Ask the Mito Doc webinar with Michio Hirano, MD, of Columbia University focused on questions related to TK2d and Kygevvi (doxecitine and doxribtimine) on Tuesday, November 25, at 11:00am ET.
CLICK HERE to register and submit questions.
Join UMDF Quarterly TK2d Support Group Meetings: We invite all TK2d families to join us for our next TK2d Virtual Support Meeting on November 19 at 12:00pm ET.
CLICK HERE to register for the November meeting – and watch for invites to regular meetings.
Our Mito Champions
Need to Connect with Us?
Call the Support Line: (888) 900-6486
Your November UMDF Newsletter: Celebrating a TK2d Therapy Approval, MELAS Survey, Mito Books, and More
Signup to receive the UMDF newsletter in your email monthly at umdf.org/newsletter-signup.
FDA Approves First-Ever TK2d Therapy
11/3/25, 5pm EST -- Earlier today, the U.S. Food and Drug Administration (FDA) approved UCB’s Kygevvi (doxecitine and doxribtimine) to treat the mitochondrial disease thymidine kinase 2 deficiency (TK2d). “It’s hard to put into words what today’s decision means for...
SPECIAL NATIONAL AUTHOR’S DAY FEATURE: Mito Patient and His Mom Talk About Self-Publishing “Children’s Chapter Adventure” Book
KSS Patient and Mom Talk About Self-Publishing Their "Children's Chapter Adventure" Book Thomas Gordon is not your typical author. Diagnosed with the mitochondrial disease Kearns-Sayre syndrome in 2014, he lives life totally blind, relies on hearing aids, and cannot...